cTAPcTAPcTAPcTAP
  • WHAT WE DO
  • HOW WE DO IT
    • Our Leadership
    • OUR SCIENTIFIC ADVISORS
    • Our Approach
  • OUR PROGRAMS
    • cTAP DUCHENNE
    • What’s Next
  • OUR IMPACT
    • Publications
    • Abstracts
    • News & Press
    • Presentations
  • PARTNER WITH US
    • Patient Organizations
    • Scientific Leaders & Researchers
    • Industry
  • CONTACT

2019 EAN Abstract – Phase 1b/2 Study of RG6206

Home / Blog / Abstracts / 2019 EAN Abstract – Phase 1b/2 Study of RG6206

cTAP Abstract for 2019 NORD Summit
Categorising trajectories and individual item changes of the NSAA in patients with DMD

2019 EAN Abstract – Phase 1b/2 Study of RG6206

A Phase 1b/2 study of the anti-myostatin adnectin RG6206 (BMS-986089) in ambulatory boys with Duchenne muscular dystrophy: A 72-week treatment update

View the Full PDF

01
Sep 2019
By SCsbox3AdminAbstractsComments Off on 2019 EAN Abstract – Phase 1b/2 Study of RG6206

Read the latest

  • Predicting multi-year changes in rise-from-floor (RFF) Velocity in Duchenne muscular dystrophy
  • A prognostic score for time to loss of hand-to-mouth ability in Duchenne muscular dystrophy
  • Functional Assessments Used in Routine Care for Duchenne Muscular Dystrophy in the United States: A Survey of Certified Duchenne Care Centers
  • cTAP Announces Novel Prognostic Score Developed for Duchenne Muscular Dystrophy Patients Offers Improved Prediction of Loss of Ambulation
  • A Prognostic Score for Time to Loss of Hand-to-Mouth Ability in Duchenne Muscular Dystrophy (DMD)

COLLABORATIVE TRAJECTORY
ANALYSIS PROJECT

501 (c) 3 nonprofit organization

Cambridge Innovative Center
One Broadway, Cambridge, MA 02142

T: 617-555-5555
E: info@ctap-nmd.org

Terms & Conditions
Privacy Policy

© 2026 Collaborative Trajectory Analysis Project. All rights reserved.

  • WHAT WE DO
  • HOW WE DO IT
    • Our Leadership
    • OUR SCIENTIFIC ADVISORS
    • Our Approach
  • OUR PROGRAMS
    • cTAP DUCHENNE
    • What’s Next
  • OUR IMPACT
    • Publications
    • Abstracts
    • News & Press
    • Presentations
  • PARTNER WITH US
    • Patient Organizations
    • Scientific Leaders & Researchers
    • Industry
  • CONTACT

Terms and Conditions - Privacy Policy